Mexidol after hemispheric ischemic stroke: EPICA placebo-controlled trial
Randomized study in people · 2017
- What was studied
- 150 randomized, 75 per arm. Per-protocol results: 61 Mexidol and 63 placebo.
- Main finding
- At days 67–71 the mean modified Rankin Score was 1.10 with Mexidol and 1.46 with placebo (p=0.04). Scores of 0–2 were reported in 59/61 vs 53/63. Serious adverse events occurred in 1/75 vs 3/75.
Reported findings and study design
Double-blind, randomized multicenter parallel groups. 75 assigned per arm, with 61 and 63 in the per-protocol analysis.
Population or model 150 randomized, 75 per arm. Per-protocol results: 61 Mexidol and 63 placebo.
Dose, route and schedule
500 mg Mexidol by intravenous infusion daily for 10 days, followed by 125 mg orally three times daily for eight weeks. The comparator followed the same schedule with matching placebo.
Protocol source ↗ · Published full-text trial tables and ClinicalTrials.gov results (NCT02793687).
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mean disability score (mRS) | 1.10 vs 1.46 points | Mexidol vs placebo, 61 vs 63 analyzed · Days 67–71 · p=0.04 |
| mRS score 0–2 | 59/61 (96.7%) vs 53/63 (84.1%) | Days 67–71 · p=0.039 |
| Mean NIHSS score | 1.7 vs 2.2 points | Days 67–71 · p=0.035 |
| Serious adverse events | 1/75 vs 3/75 | No deaths reported in either arm |
The journal reported no significant between-arm differences on the Barthel Index, Frontal Assessment Battery or cognitive screening questionnaire. The 2018 translation and later EPICA subgroup reports use this cohort.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- Twenty-six randomized participants were outside the per-protocol analysis. The trial registry first posted after completion.
- The 2018 translation, age subgroup report, and later analysis combining EPICA with MIR reuse trial participants. EPICA and MIR ran in different periods.
Related publications may describe some of the same participants or experiments.
Source details
2018 journal English translation of the 2017 original, checked with registry results.
Sources checked
Citation
L. V. Stakhovskaya, N. A. Shamalov, D. R. Khasanova, et al.. Mexidol after hemispheric ischemic stroke: EPICA placebo-controlled trial Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(3 Suppl 2):55–65. NCT02793687.
Study source ↗ · DOI 10.17116/jnevro20171173255-65 · Bibliography entry · Link to this summary